|
WO2020013108A1
|
|
Pharmaceutical composition for preventing or treating mitochondrial diseases
|
|
WO2015105064A1
|
|
Pharmaceutical composition for prevention or treatment of retinal disorders
|
|
CN102197028A
|
|
Piperidine derivative, piperazine derivative and agent for treatment of disease involving central nervous system disorders
|
|
KR20110077015A
|
|
Cyclohexylamine derivative containing phenyl group, and therapeutic agent for diseases accompanied by central nervous system disorders
|
|
JP2012001437A
|
|
Pharmaceutical for prevention or treatment of hearing loss and secondary symptom of hearing loss
|
|
AU2007218086A1
|
|
Piperazine derivatives
|
|
CA2633568A1
|
|
Piperidine and piperazine derivatives
|
|
CA2668766A1
|
|
Sigma ligands for neuronal regeneration and functional recovery
|
|
AU2006308873A1
|
|
Sigma ligands for neuronal regeneration and functional recovery
|
|
WO2008096189A2
|
|
Piperidine and piperazine derivatives
|
|
CA2617346A1
|
|
Piperazine derivatives
|
|
US2006014753A1
|
|
Sigma ligands for neuronal regeneration and functional recovery
|
|
EP1635805A2
|
|
Sigma ligands for neuronal regeneration and functional recovery
|
|
WO03011276A1
|
|
Nf?b inhibitor
|
|
WO03004065A1
|
|
Method of transporting physiological polymer using protein having rxp repeated sequence
|
|
JP2004026695A
|
|
Aqueous eye drop
|
|
JP2004016072A
|
|
Method for intercellular transportation of physiologically active substance
|
|
JP2004331501A
|
|
Anti-inflammatory agent containing new compound or its derivative
|
|
JP2002218975A
|
|
Attenuated simple herpesvirus
|
